Zacks Research Has Positive Outlook for TEVA FY2025 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Stock analysts at Zacks Research raised their FY2025 earnings estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Thursday, April 3rd. Zacks Research analyst R. Department now expects that the company will earn $2.48 per share for the year, up from their prior forecast of $2.42. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.69 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.80 EPS, Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $2.62 EPS and FY2027 earnings at $2.82 EPS.

Several other analysts have also issued reports on the company. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $13.91 on Monday. The stock has a market capitalization of $15.77 billion, a P/E ratio of -9.59, a PEG ratio of 1.44 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 12-month low of $12.51 and a 12-month high of $22.80. The stock has a 50-day moving average price of $16.36 and a 200-day moving average price of $17.99.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

Institutional Trading of Teva Pharmaceutical Industries

Several large investors have recently added to or reduced their stakes in TEVA. Stifel Financial Corp lifted its position in shares of Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in shares of Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares during the period. Pinnbrook Capital Management LP bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $4,966,000. Asset Management One Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 14.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after purchasing an additional 58,413 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $3,340,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.